Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells 21,700 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 21,700 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $24.18, for a total value of $524,706.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Anish Patel also recently made the following trade(s):

• On Friday, October 18th, Anish Patel sold 716 shares of Enliven Therapeutics stock. The stock was sold at an average price of $30.00, for a total value of $21,480.00.

Enliven Therapeutics Stock Performance

Shares of ELVN opened at $21.74 on Friday. Enliven Therapeutics, Inc. has a 1 year low of $10.90 and a 1 year high of $30.03. The stock has a market capitalization of $1.06 billion, a PE ratio of -11.44 and a beta of 1.04. The stock has a 50-day simple moving average of $24.54 and a 200-day simple moving average of $24.39.

Wall Street Analyst Weigh In

ELVN has been the subject of several research reports. BTIG Research initiated coverage on Enliven Therapeutics in a research report on Friday, December 13th. They issued a “buy” rating and a $42.00 target price for the company. Robert W. Baird lifted their price objective on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, November 15th. Finally, HC Wainwright reiterated a “buy” rating and set a $37.00 target price on shares of Enliven Therapeutics in a report on Tuesday, October 1st. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $38.25.

Institutional Trading of Enliven Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. FMR LLC increased its position in shares of Enliven Therapeutics by 10.6% in the 3rd quarter. FMR LLC now owns 6,296,179 shares of the company’s stock valued at $160,804,000 after purchasing an additional 601,611 shares during the last quarter. First Turn Management LLC purchased a new position in Enliven Therapeutics in the second quarter valued at $9,657,000. Lord Abbett & CO. LLC acquired a new stake in Enliven Therapeutics in the third quarter valued at $8,199,000. Janus Henderson Group PLC lifted its holdings in Enliven Therapeutics by 43.0% during the 3rd quarter. Janus Henderson Group PLC now owns 1,041,724 shares of the company’s stock worth $26,611,000 after buying an additional 313,019 shares during the last quarter. Finally, Ally Bridge Group NY LLC acquired a new position in shares of Enliven Therapeutics during the 3rd quarter worth about $5,998,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.